Immutep
Search :
Corporate Information
Product Development
Clinical Trials
Business Strategy
Investor Relations
Contact Us
News
May 20, 2012
Topics:
Corporate Information
Product Development
Clinical Trials
Business Strategy
Investor Relations
Contact Us
News
>
Page bottom
Home
»
News
»
First Funding
First Funding
IMMUTEP closes funding to develop novel therapeutic vaccines. Click to read the complete
Press Release
(PDF Format).
Published 04/2004 by
admin@immutep.com
© 2002 Immutep, S.A.
Press Release
04/2012 -
Immutep and Lonza Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact® IMP321
Immutep and Lonza announced today an agreement for cell line ...
02/2012 -
Interview Frederic Triebel with PharmaTelevision
Get the Flash ...
01/2011 -
Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
Immutep S.A. announced today the execution of a licence agreement ...
09/2010 -
Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
Clinical research paper describes IMP321’s potency in achieving ...
05/2010 -
Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
Immutep S.A. announced today that the final results from its Phase ...
IMMUTEP closes funding to develop novel therapeutic vaccines. Click to read the complete Press Release (PDF Format).
